Spark Therapeutics, Inc. (ONCE)

[Jp111]

I am. Everything's down today so it's been a great opportunity to buy more. The fact that ONCE is at a phase 3 trial for its product will spur this stock further. The product is set for 2016 market release so be patient. But this will shoot up to 115 by that time and in the meantime away between 70-85.

[StockNet]

Anyone keeping an eye on this? I am interested in this company but there seems to be little discussion recently.

I am currently doing my DD and thinking of taking a position on this pullback.

Thoughts?

Thanks!

[Jp111]

$88 by the end of the week?

[Jp111]

Back in @$70 - will sell at the next spike @$80

[cty]

8K out

Cowen health presentation slides..... look really good

http://www.sec.gov/Archives/edgar/data/1609351/000119312515075606/d882785dex991.htm

[cty]

broke it and held it!

[Natetex]

Can we break and hold $60 today? Wow this is on a tear. Glad I'm an owner.

[north40000]

Much obliged for your report....There is a lot to research and keep track of these days. Will look into ONCE to hold in addition to OCAT
which has traded well this morning.

[cty]

Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference
Print
Alert
SPARK THERAPEUTICS, INC. (NASDAQ:ONCE)
Intraday Stock Chart

Today : Thursday 26 February 2015
Click Here for more SPARK THERAPEUTICS, INC. Charts.

PHILADELPHIA, Feb. 26, 2015 /PRNewswire/ -- Spark Therapeutics (NASDAQ: ONCE) announced today that members of its management team will participate in the Cowen and Company Health Care Conference on Wednesday, March 4, 2015 at 9:40 a.m., Eastern, at the Boston Marriott Copley Place.

To access the live webcast of a Spark Therapeutics presentation from the Cowen conference, please visit the "Upcoming Events" section within the "News and Events" section of the Spark Therapeutics website at www.sparktx.com. A replay of the webcast will be available on the website for 90 days following the conference.

About Spark Therapeutics

Spark is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. Spark's initial focus is on treating orphan diseases where no, or only palliative, therapies exist. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully enrolled pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark is leveraging the experience and technology utilized in the development of SPK-RPE65 to address a broad spectrum of blinding conditions, starting with the development of SPK-CHM for the potential treatment of choroideremia, currently in a Phase 1/2 clinical trial. Spark also is establishing a pipeline of gene therapy candidates to treat hematologic disorders and neurodegenerative diseases, including through a global collaboration with Pfizer Inc. around the development and commercialization of its SPK-FIX program for the treatment of hemophilia B. Spark's integrated gene therapy platform builds on two decades of research, development and manufacturing at The Children's Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com

[cty]

hey north

I missed the report last night, listened to it this morning. While i am a die hard fan of OCAT, i think ONCE does have some tremendous potential in treating potential diseases that may be similar , but probably different than OCAT. OCAT is the first FDA approved stem cell company , ONCE is on track to be the first FDA approved gene therapy company.

They are in phase 3 with results coming out in mid 2015. I heard about the company about 4 months ago and have been waiting for the IPO. When the debut came , it was on the same day as Shake Shack which took most of the attention that day. Fine with me, I bought it that day and have been holding since.

I think this company has a PPS of 100.00 and beyond. If phase 3 results are good, it could be another ICPT. Just my opinion.


I own much more OCAT, which is uplisting today! I will be holding onto ONCE for some time as well.

[north40000]

ONCE: As cty knows, OCAT represents a formidable force in the field of regenerative medicine itself. It up-lists to Nasdaq Global exchange tomorrow morning.

Cty, or others, is there an informed comparison that can be made between OCAT and ONCE?

I will continue reading here myself. My interest stems[no pun] from a ~5:30-5:45 pm segment on CNBC this evening.

[cty]

http://tickerreport.com/banking-finance/426599/spark-therapeutics-receives-new-coverage-from-analysts-at-cowen-and-company-once/



Spark Therapeutics Receives New Coverage from Analysts at Cowen and Company (ONCE)

Posted by Stephan Byrd on Feb 24th, 2015 // No Comments
Share on StockTwits

Spark Therapeutics logoInvestment analysts at Cowen and Company initiated coverage on shares of Spark Therapeutics (NASDAQ:ONCE) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

ONCE has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of Spark Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Spark Therapeutics in a research note on Tuesday. They set an “overweight” rating on the stock. Analysts at Rodman & Renshaw initiated coverage on shares of Spark Therapeutics in a research note on Sunday. They set a “buy” rating and a $71.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of Spark Therapeutics in a research note on Thursday, February 19th. They set a “buy” rating and a $72.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $71.50.

Spark Therapeutics (NASDAQ:ONCE) opened at 56.68 on Tuesday. Spark Therapeutics has a 52 week low of $40.50 and a 52 week high of $57.24. The stock’s 50-day moving average is $46.85 and its 200-day moving average is $46.85.

Spark Therapeutics, Inc is engaged in the field of gene therapy. The Company develops one-time, life-altering treatments for patients suffering from debilitating genetic diseases. The Company is focused on treating rare diseases where no, or only palliative therapies exist. The Company addresses a range of debilitating genetic diseases including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases.

[cty]

http://m.seekingalpha.com/article/2935056-ipo-quiet-period-expiration-spark-therapeutics-inc


Summary

ONCE develops gene therapy that targets debilitating genetic diseases.
The 25-day quiet period on ONCE will end 2.24.2015, allowing its IPO underwriters to publish reports and recommendations for the first time; this could lead to an uptick in price.
Recent research shows above-market returns in the days surrounding a firm's quiet period expiration, particularly for firm with strong underwriters, like ONCE.
We suggest investors strongly consider buying into ONCE, ahead of the event, for full gains.

[cty]

Roth Capital Initiates Coverage on Spark Therapeutics at Buy, Announces $71.00 PT
Charles Gross , Benzinga Staff Writer

Read more: http://www.benzinga.com/news/15/02/5254391/roth-capital-initiates-coverage-on-spark-therapeutics-at-buy-announces-71-00-pt#ixzz3SCPdLxff

[cty]

http://www.prnewswire.com/news-releases/spark-therapeutics-appoints-industry-leader-dr-elliott-sigal-former-executive-vice-president-and-chief-scientific-officer-of-bristol-myers-squibb-to-board-of-directors-244867921.html

[TheFinalCD]

47.75

[crudeoil24]

Specific pricing information in company contracts with clients may qualify for confidential treatment. This is because exposing such information would most likely hurt a company's financial performance as competitors can use this information to undercut the company.

These requests are not usually granted by the SEC at will, but in certain instances it can be deemed in the best interest of the company and investors to keep the information confidential for a certain period of time.

[cty]

Confidential Order Treatment


https://www.sec.gov/Archives/edgar/data/1609351/999999999715000569/filename1.pdf



Spark Therapeutics
, In
c. submitted an application under
R
ule 406 requesting
confidential treatment for information it excluded from the Exhibits to a Form S
-
1
registration statement filed on
December 30, 2014
, as amended
.
Based on representations by
Spark Therapeutics
, Inc. that this inf
ormation
qualifies as confidential commercial or financial information under the Freedom of
Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
not to publicly disclose it. Accordingly, excluded information from the fol
lowing
exhibits will not be released to the public for the time periods specified:
Exhibit 10.9
through
September 24, 2017
Exhibit 10.10
through
September 24, 2017
Exhibit 10.11
through
September 24, 2017
Exhibit 10.13
through
Septembe
r 24, 2017
Exhibit 10.14
through
December 11, 2017
Exhibit 10.15
through
September 24, 2017
Exhibit 10.16
through
September 24, 2017
Exhibit 10.17
through
September 24, 2017
Exhibit 10.18
through
December 11, 2017
Exhibit 10.19
thro
ugh
December 11, 2017
For the Commission
, by the Division of Corporation Finance, pursuant to
delegated authority
:
Brent J. Fields
Secretary

[cty]

that among other things, yes. but that statement alone is why this stock could be worth 100.00 or more

[crudeoil24]

I agree with you SM. Excellent trade! >>> Day is young. ONCE may turn around and go green with tutes loading shares today. I picked up some 45.21's earlier. >> Just trading, but have a few and long in my other IRA account.

[TheFinalCD]

TY, I see ONCE run didn't carry through to today

the trade on these IPO's is 1st day in & out, wait for next!

that's where the ez$ is

-imo

[crudeoil24]

Potential to be first FDA approved gene therapy product. That's what I'm talking about!

[cty]

im in and holding strong. not looking to sell shares , this company has tremendous potential..

[crudeoil24]

I hear you, DOW is plunging!

[KingDMC]

Market is slowly crashing man I'm taking what profit I have across the board.

[crudeoil24]

This stock will run on news. Good to re-enter with a catalyst. Retail collecting profits here.

[KingDMC]

Took profit not holding on to anything in this shit market.

[Already made it]

Smart money is right on this one.

IPO are initial "public" offerings big firms don't get to keep any shares. But they do have rights & warrants they can exercise after a certain date

I Havnt read into the prospectus, but it seems like the float is 7M shares.

All traded between $40 - $50

[KingDMC]

I skimmed through the Website yes good stuff from what I read.

[KingDMC]

Nice. Would love to see a run to $55 Monday.

[TradeSmart.ai]

At least one IPO did good today lol

[crudeoil24]

Congrats, I am holding 740 shares. started buying @ 46

Should of bought in low 40's >>>> buy I did not know that this is first potential FDA approved gene therapy product.

Did you see their WEB-SITE the boy was cured of his blindness?

Can't wait to see media coverage . hope we plow through the 50's next week.

[TheFinalCD]

http://fortune.com/2015/01/30/todays-huge-ipo-news-no-not-shake-shack/

ONCE UPON AN IPO

[crudeoil24]

I'm holding as well! >>> Bought from 46 on.

[crudeoil24]

Kabooom! Gapper Monday!

[crudeoil24]

Most shares are held days before by JPM and other big Wall Street firms. Very little left for trading. You know that. ONCE shares were very few to be had when it opened. That's why 1M float is at 50 now.

[TheFinalCD]

(+$10) COONGRAT$$$$$ KDMC

[TheFinalCD]

I don't give a hoot what Scottrade says man, IPO is an IPO all shares go out in the offering, unless you can prove otherwise

I say the float is 7M
you say its 1M

Id like to see some proof other than Scottrade data

cant go by that!

!@#$ scott

[KingDMC]

Idk but up 10 points on this bad boy so far. Shoulda doubled down when it touched 40.60. $55 Monday.

[crudeoil24]

51.50

[TheFinalCD]

$51.50= wow

[crudeoil24]

Check your SCOTTRADE account .... Shows 1M float.

[TheFinalCD]

please explain an IPO is Intial Public Offering

they have 7M shares in the offering...


so the float would be 7M, please show proof, that insiders own 6M out of the 7M offered

something aint right!

[crudeoil24]

7M = OS

1M = FLOAT THAT IS TRADING.

Company controls this gem . The big boys Pfizer, Merck can't buy this company.

ONCE is in full control, >>>> Maybe a JV.

[TheFinalCD]

7M offering so how does an IPO have a float smaller than the offering???

http://finance.yahoo.com/news/spark-therapeutics-announces-pricing-initial-120000079.html

[crudeoil24]

SHAKA SHAKE SHAKA! OPPS WRONG BOARD!...LOL

[crudeoil24]

Running in the 50's

[crudeoil24]

The Company addresses a range of debilitating genetic diseases including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases.

[crudeoil24]

I bet we have a nice upside gapper Monday.

Will join Russel 1000 > that will create more upside as well.

Funds buying large blocks today.

Plenty of media attention this weekend, especially being the potential FDA first approved gene therapy product.

Check website, cures blindness, etc. in trials.

[KingDMC]

$55 Monday!